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Résumé en
anglais
Purpose To determine the safety and the efficacy of paclitaxel and capecitabine as
second-line combination chemotherapy after failure of platinum regimens in
advanced gastric cancer. Methods Patients with histologically proven gastric cancer
and measurable metastatic disease received capecitabine 825 mg/m2 twice daily
(1,650 mg/m2 per day) on days 1–14 and paclitaxel 175 mg/m2 by intravenous
infusion on day 1 every 3 weeks until disease progression or unacceptable toxicities.
Results Between June 2003 and October 2005, 26 patients, of median age 59 years
(range 41–84 years) were included in the study and were treated by
paclitaxel/capecitabine combination. Overall response rate was 34.6% (95%CI =
17.2–55.7%) with one complete response and 42.3% (95%CI = 17.2–55.7%) of
patients achieved a stable disease. Median progression-free survival was 4.5 months
(95%CI = 4–4.5 months). Median overall survival was 7.5 months (95%CI = 6–10
months). Cumulated overall survival including cisplatin regimens was 15.5 months
(95%CI = 11–18 months). Grade 3/4 adverse events included alopecia (30.8%),
neutropenia (11.5%), hand foot skin reaction (11.5%), neuropathy (11.5%),
arthralgias (7.5%), and anemia (3.8%). Conclusions Paclitaxel and capecitabine
combination was safe and effective in advanced gastric cancer after failure of
cisplatin regimens. The cumulated overall survival of 15.5 months suggests a
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